Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities

European Journal of Clinical Pharmacology

Volumn 54, Issue 11, 1999, Pages 869-876

  Fuchs, P ^a   Haefeli, W E ^a,b   Ledermann, H R ^c   Wenk, M ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Geriatrische Universitatsklinik   (Switzerland)

Author keywords

Allopurinol; CYP1A2; N acetyltransferase; Xanthine oxidase

Indexed keywords

ACYLTRANSFERASE; ALLOPURINOL; CAFFEINE; CYTOCHROME P450; DRUG METABOLITE; OXIPURINOL; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ALLOPURINOL; ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL MARKERS; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OXYPURINOL; PROSPECTIVE STUDIES; URIC ACID; XANTHINE OXIDASE;

EID: 0032890885     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050569     Document Type: Article

References (39)

1. 1. Evans DA (1993) N-Acetyltransferase. In: Genetic factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge University Press, Cambridge, pp 211-302
2. 2. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, et al (1993) Genotype phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14: 1689-1692
3. 3. Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237-5241
4. 4. Grant DM, Tang BK, Kalow W (1984) A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17: 459-464
5. 5. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA (1994) Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 8: 333-337
6. 6. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT (1979) N-acetyltransferase phenotype and risk in urinary-bladder cancer: approaches on molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71-79
7. 7. Rieder MJ, Shear NH, Kanee BK, Tang BK, Spielberg SP (1991) Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity. Clin Pharmacol Ther 49: 13-17
8. 8. Rothen JP, Haefeli WE, Meyer UA, Todesco L, Wenk M (1998) Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo. Pharmacogenetics 8 (in press)
9. 9. Zysset T, Peretti E (1986) Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine. Eur J Clin Pharmacol 30: 463-466
10. 10. Campbell ME, Spielberg SP, Kalow W (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42: 157-165
11. 11. Grant DM, Tang BK, Campbell ME, Kalow W (1986) Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 21: 454-458
12. 12. Tang BK, Kadar D. Qian L, Iriah J, Yip J, Kalow W (1991) Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49: 648-657
13. 13. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer UA, Haefeli WE (1996) N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 60: 62-67
14. 14. Tang BK, Kadar D, Kalou W (1987) An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 42: 509-513
15. 15. Denaro CP, Wilson M, Jacob P. Benowitz NL (1996) Validation of urine caffeine metabolite ratios with use of stable isotope-labelled caffeine clearance. Clin Pharmacol Ther 59: 284-296
16. 16. Evans DA, White TA (1964) Human acetylation polymorphism. J Lab Clin Med 63: 394-403
17. 17. Peters JH, Gordon GR, Brown P (1965) The relationships between the capacities of human subjects to acetylate isoniazid sulfonilamide and sulfomethazine. Life Sci 4: 99-107
18. 18. Elion GB (1978) Allopurinol and other inhibitors of urate synthesis. In: Kelley WN, Weiner IM, (eds) Uric acid. Springer, Berlin Heidelberg New York 485-514
19. 19. Relling MV, Lin JS, Ayers GD, Evans WE (1992) Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 52: 643-658
20. 20. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW (1990) Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 47: 470-477
21. 21. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF (1992) Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2: 116-127
22. 22. Miyazaki H, Matsunaga Y, Yoshida K, Arakawa S, Hashimoto M (1983) Simultaneous determination of plasma and urinary uric acid, xanthine, hypoxanthine, allopurinol, oxipurinol, orotic acid, orotidine and creatinine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 274: 75-85
23. 23. De Vrics JX, Voss A, Kutschker C, Reiter S (1993) Simultaneous determination of allopurinol and oxipurinol in human plasma and urine by high-performance liquid chromatography. Drug Res 43: 1072-1075
24. 24. De Lean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves:application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102
25. 25. Birkett DJ, Miners JO, Valente L, Lillywhite KJ, Day RO (1997) 1-Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect. Br J Clin Pharmacol 43: 197-200
26. 26. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H (1992) Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 43: 399-403
27. 27. Notarianni LJ, Dobrocky P, Godlewski G, Jones RW, Bennett PN (1996) Caffeine as a metabolic probe: NAT2 phenotyping. Br J Clin Pharmacol 41: 169-173
28. 28. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM (1981) Risk factors of isoniazid (INH)-induced liver dysfunclion. J Clin Gastroenterol 3: 271-279
29. 29. Day RO, Miners JO, Birkett DJ, Whitehead A, Graham GG (1988) Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. Br J Clin Pharmacol 26: 431-436
30. 30. Hamelin BA, Xu K, Valle F, Manseau L, Richer M, LeBel M (1994) Caffeine metabolism in cystic fibrosis: enhanced xanthine oxidase activity. Clin Pharmacol Ther 56: 521-529
31. 31. Vincent-Viry M, Braz Vieira da Silva Pontes Z, Gneguen R, Galteau MM, Siest G (1994) Segregation analyses of four urinary caffeine metabolite ratios implicated in the determination of human acetylation phenotypes. Genet Epidemiol 11: 115-129
32. 32. Ahmad RA, Rogers HJ, Vandenburg M, Wright P (1981) Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation. Br J Clin Pharmacol 12: 83-86
33. 33. Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53: 503-514
34. 34. Lelo A, Kjellen G, Birkett DJ, Miners JO (1989) Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine. J Pharmacol Exp Ther 248: 315-319
35. 35. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Iayes J, Savdic E (1988) Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 26: 423-428
36. 36. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW (1997) N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 62: 261-271
37. 37. Grant DM, Tang BK, Kalow W (1983) Variability in caffeine melabolism. Clin Pharmacol Ther 33: 591-602
38. 38. Gu L, Gonzalez FJ, Kalow W, Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 2: 73-77
39. 39. Campbell ME, Grant DM, Tadanobu I, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15: 237-249